Does LENALIDOMIDE Cause Second primary malignancy? 244 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 244 reports of Second primary malignancy have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.1% of all adverse event reports for LENALIDOMIDE.
244
Reports of Second primary malignancy with LENALIDOMIDE
0.1%
of all LENALIDOMIDE reports
50
Deaths
44
Hospitalizations
How Dangerous Is Second primary malignancy From LENALIDOMIDE?
Of the 244 reports, 50 (20.5%) resulted in death, 44 (18.0%) required hospitalization, and 26 (10.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 244 reports have been filed with the FAERS database.
What Other Side Effects Does LENALIDOMIDE Cause?
Diarrhoea (27,576)
Fatigue (22,956)
Death (19,213)
Off label use (17,017)
Rash (15,794)
Pneumonia (14,807)
Plasma cell myeloma (14,191)
Neuropathy peripheral (10,215)
White blood cell count decreased (9,996)
Constipation (9,635)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LENALIDOMIDE Alternatives Have Lower Second primary malignancy Risk?
LENALIDOMIDE vs LENIOLISIB
LENALIDOMIDE vs LENOGRASTIM
LENALIDOMIDE vs LENVATINIB
LENALIDOMIDE vs LEPONEX
LENALIDOMIDE vs LERCANIDIPINE